Cost‐Effectiveness of Surgery Versus Organ Preservation in Advanced Laryngeal Cancer

Abstract

Objective Treatment decision‐making for patients with laryngeal cancer consists of a complex trade‐off between survival and quality of life. For decision makers on coverage and guidelines, costs come in addition to this equation. Our aim was to perform a cost‐effectiveness analysis of surgery (laryngectomy with or without radiotherapy) versus organ preservation (OP: radiotherapy, chemo‐ and/or bioradiation) in advanced laryngeal cancer patients from a healthcare perspective. Methods A cost‐effectiveness analysis was conducted using a Markov model. For each modality, data on survival and quality‐adjusted life years (QALYs) were sourced from relevant articles in agreement with experts, and national benchmark cost prices were included regarding treatment, follow‐up, adverse events, and rehabilitation. Results Total QALYs of the surgical approach (6.59) were substantially higher compared to the OP approach (5.44). Total lifetime costs were higher for the surgical approach compared to the OP approach, namely €95,881 versus €47,233. The surgical approach was therefore more effective and more costly compared to OP, resulting in an incremental cost‐effectiveness ratio of €42,383/QALY. Conclusion Based on current literature, surgical treatment was cost‐effective compared to OP in advanced laryngeal cancer within most willingness‐to‐pay thresholds. The study provides information on the survival adjusted for quality of life in combination with costs of two different approaches for advanced laryngeal cancer, relevant for patients, physicians, and policy makers. As financial toxicity is a relevant aspect in this population, collection of real‐world data on country‐specific costs and utilities is strongly recommended to enable further generalization. Level of Evidence N/A. Laryngoscope, 131:E509–E517, 2021

Socioeconomic Influence on Speech Rehabilitation After Total Laryngectomy

“…Estimated from various cost-effectiveness analyses, the yearly cost for prosthesis maintenance and replacement range from $750 to $3600. [13][14][15][16] Most private insurance providers consider the placement and replacement of VPs medically necessary following total laryngectomy. According to Aetna policy number 0560, replacement is covered every 3 to 6 months.…”

Cost-effectiveness of hypofractionated versus conventional fractionated radiotherapy for the treatment of men with early glottic cancer: a study in the Brazilian public and private health system

“…Markov and partitioned survival models (PSM) are commonly used for the cost-effective analysis of cancer treatments. In this study, we have chosen to use the Markov model due to the lack of individual patient data and the simplicity of modeling the course of disease based on previous Markov models [ 29 , 30 ]. Moreover, there is no evidence that Markov and PSM lead to different results, and both are recommended as appropriate for cancer treatments [ 45 ].…”

“…Few studies present a Markov model to illustrate possible health states for larynx cancer. The study by [ 29 ] shows a Markov model for advanced laryngeal cancer and, due to that, does not include the ‘local failure’ state. The study by [ 30 ] proposes a Markov model for locally advanced head and neck cancer and presents health states similar to the ones elaborated by the present study.…”

The analysis of tumor-infiltrating immune cell and ceRNA networks in laryngeal squamous cell carcinoma

“…However, the complications from these treatments, as well as relapses and metastasis affecting the prognosis, can seriously interfere with a patient’s normal life. [4] Therefore, early prevention, diagnosis, personalized treatment, and the search for precise targeted therapeutic drugs are of great significance to increase the survival rate of patients. The treatment of LSCC requires the selection of appropriate treatment options according to the patient’s clinical stages, metastasis ranges, tumor sizes, and ages.…”